Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Epistasis01:39

Epistasis

In addition to multiple alleles at the same locus influencing traits, numerous genes or alleles at different locations may interact and influence phenotypes in a phenomenon called epistasis. For example, rabbit fur can be black or brown depending on whether the animal is homozygous dominant or heterozygous at a TYRP1 locus. However, if the rabbit is also homozygous recessive at a locus on the tyrosinase gene (TYR), it will have an unshaded coat that appears white, regardless of its TYRP1...
Background and Environment Affect Phenotype02:27

Background and Environment Affect Phenotype

Although the genetic makeup of an organism plays a major role in determining the phenotype, there are also several environmental factors, such as temperature, oxygen availability, presence of mutagens, that can alter an organism’s phenotype.
An example of how genetic background affects phenotype can be seen in horses. The Extension gene in horses is responsible for their coat color. A wild-type gene (EE) produces black pigment in the coat, while a mutant gene (ee) produces red pigment. A...
Epistasis Analysis01:09

Epistasis Analysis

Although Mendel chose seven unrelated traits in peas to study gene segregation, most traits involve multiple gene interactions that create a spectrum of phenotypes. When the interaction of various genes or alleles at different locations influences a phenotype, this is called epistasis. Epistasis often involves one gene masking or interfering with the expression of another (antagonistic epistasis). Epistasis often occurs when different genes are part of the same biochemical pathway. The...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ganglion impar block in chronic cancer-related pain - A review of the current literature.

Revista espanola de anestesiologia y reanimacion·2024
Same author

Achievement of Target Gain Larger than Unity in an Inertial Fusion Experiment.

Physical review letters·2024
Same author

Influenza vaccination in older adults and patients with chronic disorders: A position paper from the Portuguese Society of Pulmonology, the Portuguese Society of Cardiology, the Portuguese Society of Diabetology, the Portuguese Society of Infectious Diseases and Clinical Microbiology, the Portuguese Society of Geriatrics and Gerontology, and the Study Group of Geriatrics of the Portuguese Society of Internal Medicine.

Pulmonology·2023
Same author

SKELETAL MUSCLE SENSITIVITY TO WASTING INDUCED BY UROTHELIAL CARCINOMA.

Experimental oncology·2023
Same author

Learning lessons from the COVID-19 pandemic for real-world evidence research in oncology-shared perspectives from international consortia.

ESMO open·2023
Same author

COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases.

ESMO open·2023

Related Experiment Video

Updated: Jun 23, 2026

Assessment of Murine Exercise Endurance Without the Use of a Shock Grid: An Alternative to Forced Exercise
07:52

Assessment of Murine Exercise Endurance Without the Use of a Shock Grid: An Alternative to Forced Exercise

Published on: August 14, 2014

Do PPARGC1A and PPARalpha polymorphisms influence sprint or endurance phenotypes?

N Eynon1, Y Meckel, M Sagiv

  • 1Genetics and Molecular Biology Laboratory, Life Sciences Division, The Zinman College of Physical Education and Sport Sciences at the Wingate Institute, Netanya, Israel. eynon@wincol.ac.il

Scandinavian Journal of Medicine & Science in Sports
|May 9, 2009
PubMed
Summary
This summary is machine-generated.

Genetic variations in PPARGC1A and PPARalpha genes influence athletic performance. Endurance athletes showed a lower frequency of the PPARGC1A Ser482 allele, suggesting a link to enhanced endurance capacity.

Related Experiment Videos

Last Updated: Jun 23, 2026

Assessment of Murine Exercise Endurance Without the Use of a Shock Grid: An Alternative to Forced Exercise
07:52

Assessment of Murine Exercise Endurance Without the Use of a Shock Grid: An Alternative to Forced Exercise

Published on: August 14, 2014

Area of Science:

  • Exercise genetics
  • Human performance

Background:

  • Peroxisome proliferator-activated receptor gamma coactivator 1 (PPARGC1A) and Peroxisome proliferator-activated receptor alpha (PPARalpha) gene polymorphisms are linked to mRNA and protein activity.
  • Genetic variations may influence athletic capabilities, particularly in endurance and sprint performance.

Purpose of the Study:

  • To investigate the frequency distribution of functional Gly482Ser (rs8192678) in PPARGC1A and G/C (rs4253778) in PPARalpha polymorphisms among Israeli athletes and healthy controls.
  • To determine the association of these genetic variations with endurance and sprint performance.

Main Methods:

  • Genotyping of 155 Israeli athletes (endurance and sprinters) and 240 healthy controls for PPARGC1A Gly482Ser and PPARalpha G/C polymorphisms.
  • Statistical analysis to compare genotype and allele frequencies between athlete groups and controls.

Main Results:

  • Significant differences in PPARGC1A Ser482Gly genotype frequencies were observed between endurance athletes and sprinters (P=0.005), and between endurance athletes and controls (P=0.0003).
  • Endurance athletes exhibited a significantly lower frequency of the PPARGC1A Ser482 allele (0.25) compared to controls (0.43, P=0.0001).
  • A trend towards a higher proportion of the PPARalpha GG genotype was noted in endurance athletes compared to sprinters (P=0.051).

Conclusions:

  • A lower frequency of the PPARGC1A Ser482 allele is associated with enhanced endurance performance.
  • A higher frequency of the PPARalpha GG genotype may also be linked to increased endurance ability.
  • These findings highlight the role of specific gene polymorphisms in determining athletic performance, particularly in endurance disciplines.